argenx SE - Special Call Transcript
Good morning. My name is Elissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the argenx Conference Call. (Operator Instructions)
Thank you. Beth DelGiacco, Vice President of Investor Relations and Corporate Communications, you may begin your conference.
Thanks, Elissa. A press release was issued earlier today announcing our decision to continue the ADHERE trial of efgartigimod for the treatment of chronic inflammatory demyelinating polyneuropathy, or CIDP, following an interim analysis and confirmation by an independent data monitoring committee. The press release can be found on our website along with the presentation for today's webcast.
Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
